PMID- 19379421
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20091228
LR  - 20140730
IS  - 1492-7535 (Print)
IS  - 1492-7535 (Linking)
VI  - 8
IP  - 3
DP  - 2004 Jul 1
TI  - Serum matrix metalloproteinase-3 in hemodialysis patients with dialysis-related 
      amyloidosis.
PG  - 219-25
LID - 10.1111/j.1492-7535.2004.01099.x [doi]
AB  - BACKGROUND: Matrix metalloproteinase-3 (MMP-3) has been linked to osteoarticular 
      destruction in rheumatic arthritis. To investigate the role of MMP-3 in 
      dialysis-related amyloidosis (DRA), we determined serum MMP-3 in long-term 
      hemodialysis (HD) patients with and without clinical manifestations of DRA. 
      METHODS: Thirty-three subjects (63% female, 3% diabetic) enrolled in the study 
      between September 2001 and June 2003. All patients underwent standard HD three 
      times per week, using high-flux dialyzers. Four patients had active DRA 
      complications (DRA patients), whereas the others (n = 29) had no evidence of DRA. 
      We determined serum concentrations of MMP-3, C-reactive protein (CRP), 
      beta(2)-microglobulin (beta(2)M), and interleukin-6 (IL-6). We also studied the 
      effects of hemodiafiltration (HDF) on inflammatory measures by transferring the 
      DRA patients from regular HD to predilution HDF. RESULTS: The DRA group had been 
      on dialysis significantly longer than the control group. Significant positive 
      correlations were observed between MMP-3 and IL-6 (R(2) = 0.5143, p < 0.0001) and 
      MMP-3 and CRP (R(2) = 0.6492, p < 0.0001). IL-6 levels increased after a single 
      dialysis treatment, but this effect was minimal with predilution HDF (the 
      increment of IL-6 levels did not exceed 10 pg/mL). Serum MMP-3 levels decreased 
      in parallel with the decrease of IL-6. CONCLUSIONS: MMP-3 serum levels increase 
      in accordance with clinical manifestations of DRA and elevated circulating levels 
      of IL-6. For the evaluation of the pathophysiologic state of DRA, serum MMP-3 may 
      be a useful predictor indicative of chronic inflammation and osteoarticular 
      disorders in DRA patients.
FAU - Ishizaki, Makoto
AU  - Ishizaki M
AD  - Kidney Center, Eijinkai Hospital, Furukawa City, Miyagi, Japan. 
      naganokc@coral.ocn.ne.jp
FAU - Matsunaga, Tomohito
AU  - Matsunaga T
FAU - Adachi, Kuniaki
AU  - Adachi K
FAU - Miyashita, Eishi
AU  - Miyashita E
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Hemodial Int
JT  - Hemodialysis international. International Symposium on Home Hemodialysis
JID - 101093910
EDAT- 2004/07/01 00:00
MHDA- 2004/07/01 00:01
CRDT- 2009/04/22 09:00
PHST- 2009/04/22 09:00 [entrez]
PHST- 2004/07/01 00:00 [pubmed]
PHST- 2004/07/01 00:01 [medline]
AID - HDI1099 [pii]
AID - 10.1111/j.1492-7535.2004.01099.x [doi]
PST - ppublish
SO  - Hemodial Int. 2004 Jul 1;8(3):219-25. doi: 10.1111/j.1492-7535.2004.01099.x.